Cardiovascular Diseases

At Medicinski Centar Hipokrat-N EOOD in Plovdiv, clinical research in cardiovascular diseases focuses on reducing major heart and stroke risks in people with established vascular disease and irregular heart rhythm. These studies are exploring new ways to improve prevention, lower complications, and better protect patients at high risk.

  • Prevention of stroke and systemic embolism in atrial fibrillation
  • Lowering the risk of major cardiovascular events in atherosclerotic cardiovascular disease
  • Evaluating therapies aimed at improving outcomes in established cardiovascular disease

Overall, this area is centered on testing new treatment options and measuring whether they can offer stronger protection than existing approaches.

Metabolism and Kidney Disease

The site is also active in metabolism-related research, especially studies linking kidney health with blood pressure control and protein loss in the urine. These trials are designed to slow the progression of chronic kidney disease and improve long-term kidney function for people living with advanced renal conditions.

  • Slowing progression in chronic kidney disease with high blood pressure
  • Reducing albuminuria and high proteinuria in kidney disease
  • Testing treatments that may better preserve kidney function over time

Research in this field is aimed at improving disease control and finding more effective ways to delay kidney decline.

Bacterial Infections and Mycoses

Another important area of research at this hospital/clinic involves bacterial infections and mycoses, with a focus on preventing recurrence of Clostridioides difficile infection. The studies are intended to improve infection control and reduce the chance that this difficult-to-treat condition returns after treatment.

  • Preventing recurrent Clostridioides difficile infection
  • Assessing new approaches to reduce infection relapse
  • Supporting better outcomes for patients with recurring intestinal infection

This line of research is centered on testing whether newer therapies can provide more reliable protection against repeat infection.